• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

VIVA 17 Round-up: Medtronic touts real-world data for In.Pact Admiral drug-coated balloon

September 12, 2017 By Sarah Faulkner

Bard’s Lutonix drug-coated balloon tested in hemodialysis arteriovenous fistulae

C.R. Bard and Becton DickinsonPaclitaxel-coated balloons have the potential to reduce restenosis in arterial applications and in small trials in hemodialysis access, according to Dr. Scott Trerotola, who presented data from a trial of C. R. Bard‘s (NYSE:BCR) Lutonix DCB at VIVA this year.

The multicenter trial evaluated the Lutonix drug-device combo in hemodialysis arteriovenous fistulae. The study enrolled 285 patients with dysfunctional AVF and all of them received percutaneous transluminal angioplasty of the lesion responsible for access dysfunction.

After PTA, researchers treated the lesions with either a paclitaxel-coated balloon or an uncoated balloon.

The study’s endpoints included postintervention target lesion primary patency at 6, 9, 12, 18 and 24 months, as well as safety.

The primary safety endpoint was met and did not differ between groups, the team reported. The six-month efficacy endpoint was not met – patients who received the DCB had a TLPP rate of 71% compared to 63% for the control group.

However, the team noted that at the end of the six-month window, the TLPP rate was superior for the DCB group compared to the control group – 64% and 53%, respectively.

At six months, interventions to maintain target lesion patency were fewer for the DCB group than the control group. After 18 months, the team reported a 37% improvement in TLPP for the DCB group compared to the control group.

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: acotecscientific, C.R. Bard, cook medical, Medtronic, Mercator MedSystems, Royal Philips, SurModics Inc.

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS